191 related articles for article (PubMed ID: 10074939)
21. Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller.
Li J; Brick P; O'Hare MC; Skarzynski T; Lloyd LF; Curry VA; Clark IM; Bigg HF; Hazleman BL; Cawston TE
Structure; 1995 Jun; 3(6):541-9. PubMed ID: 8590015
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.
Reiter LA; Rizzi JP; Pandit J; Lasut MJ; McGahee SM; Parikh VD; Blake JF; Danley DE; Laird ER; Lopez-Anaya A; Lopresti-Morrow LL; Mansour MN; Martinelli GJ; Mitchell PG; Owens BS; Pauly TA; Reeves LM; Schulte GK; Yocum SA
Bioorg Med Chem Lett; 1999 Jan; 9(2):127-32. PubMed ID: 10021913
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain.
Stura EA; Visse R; Cuniasse P; Dive V; Nagase H
FASEB J; 2013 Nov; 27(11):4395-405. PubMed ID: 23913860
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor.
Hashimoto H; Takeuchi T; Komatsu K; Miyazaki K; Sato M; Higashi S
J Biol Chem; 2011 Sep; 286(38):33236-43. PubMed ID: 21813640
[TBL] [Abstract][Full Text] [Related]
25. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor.
Lovejoy B; Cleasby A; Hassell AM; Longley K; Luther MA; Weigl D; McGeehan G; McElroy AB; Drewry D; Lambert MH
Science; 1994 Jan; 263(5145):375-7. PubMed ID: 8278810
[TBL] [Abstract][Full Text] [Related]
26. Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.
Foley LH; Palermo R; Dunten P; Wang P
Bioorg Med Chem Lett; 2001 Apr; 11(8):969-72. PubMed ID: 11327602
[TBL] [Abstract][Full Text] [Related]
27. Structure of recombinant mouse collagenase-3 (MMP-13).
Botos I; Meyer E; Swanson SM; Lemaître V; Eeckhout Y; Meyer EF
J Mol Biol; 1999 Oct; 292(4):837-44. PubMed ID: 10525409
[TBL] [Abstract][Full Text] [Related]
28. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
Heim-Riether A; Taylor SJ; Liang S; Gao DA; Xiong Z; Michael August E; Collins BK; Farmer BT; Haverty K; Hill-Drzewi M; Junker HD; Mariana Margarit S; Moss N; Neumann T; Proudfoot JR; Keenan LS; Sekul R; Zhang Q; Li J; Farrow NA
Bioorg Med Chem Lett; 2009 Sep; 19(18):5321-4. PubMed ID: 19692239
[TBL] [Abstract][Full Text] [Related]
29. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure.
Lang R; Kocourek A; Braun M; Tschesche H; Huber R; Bode W; Maskos K
J Mol Biol; 2001 Sep; 312(4):731-42. PubMed ID: 11575928
[TBL] [Abstract][Full Text] [Related]
30. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase.
Elkins PA; Ho YS; Smith WW; Janson CA; D'Alessio KJ; McQueney MS; Cummings MD; Romanic AM
Acta Crystallogr D Biol Crystallogr; 2002 Jul; 58(Pt 7):1182-92. PubMed ID: 12077439
[TBL] [Abstract][Full Text] [Related]
31. Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.
Feng Y; Likos JJ; Zhu L; Woodward H; Munie G; McDonald JJ; Stevens AM; Howard CP; De Crescenzo GA; Welsch D; Shieh HS; Stallings WC
Biochim Biophys Acta; 2002 Jul; 1598(1-2):10-23. PubMed ID: 12147339
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself.
Lovejoy B; Hassell AM; Luther MA; Weigl D; Jordan SR
Biochemistry; 1994 Jul; 33(27):8207-17. PubMed ID: 8031754
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
[TBL] [Abstract][Full Text] [Related]
34. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
[TBL] [Abstract][Full Text] [Related]
35. Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics.
Hou T; Zhang W; Xu X
J Comput Aided Mol Des; 2002 Jan; 16(1):27-41. PubMed ID: 12197664
[TBL] [Abstract][Full Text] [Related]
36. The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.
Steinman DH; Curtin ML; Garland RB; Davidsen SK; Heyman HR; Holms JH; Albert DH; Magoc TJ; Nagy IB; Marcotte PA; Li J; Morgan DW; Hutchins C; Summers JB
Bioorg Med Chem Lett; 1998 Aug; 8(16):2087-92. PubMed ID: 9873491
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.
Bailey S; Bolognese B; Faller A; Louis-Flamberg P; MacPherson DT; Mayer RJ; Marshall LA; Milner PH; Mistry J; Smith DG; Ward JG
Bioorg Med Chem Lett; 1999 Nov; 9(21):3165-70. PubMed ID: 10560745
[TBL] [Abstract][Full Text] [Related]
38. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily.
Dhanaraj V; Ye QZ; Johnson LL; Hupe DJ; Ortwine DF; Dunbar JB; Rubin JR; Pavlovsky A; Humblet C; Blundell TL
Structure; 1996 Apr; 4(4):375-86. PubMed ID: 8740360
[TBL] [Abstract][Full Text] [Related]
39. Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library.
Deng SJ; Bickett DM; Mitchell JL; Lambert MH; Blackburn RK; Carter HL; Neugebauer J; Pahel G; Weiner MP; Moss ML
J Biol Chem; 2000 Oct; 275(40):31422-7. PubMed ID: 10906330
[TBL] [Abstract][Full Text] [Related]
40. Impact of mobility on structure-based drug design for the MMPs.
Moy FJ; Chanda PK; Chen J; Cosmi S; Edris W; Levin JI; Rush TS; Wilhelm J; Powers R
J Am Chem Soc; 2002 Oct; 124(43):12658-9. PubMed ID: 12392402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
